$1 Billion Boost for BridgeBio as Blockbuster Drugs Near Launch
Event summary
- $1 billion in preferred equity raised from Sixth Street and HealthCare Royalty (KKR) at a >100% premium to BridgeBio’s 30-day VWAP.
- Funding strengthens balance sheet for three potential blockbuster U.S. product launches within 12 months: BBP-418, encaleret, and infigratinib.
- Attruby® continues growth as a multi-billion-dollar blockbuster drug.
- Series A Cumulative Convertible Participating Preferred Stock issued with no maturity date or redemption at holder’s option.
The big picture
BridgeBio’s $1 billion raise underscores investor confidence in its pipeline of genetic condition therapies, particularly as it prepares for multiple blockbuster launches. The deal reflects a broader trend of flexible capital solutions targeting late-stage biopharma companies with high-impact, small-population drugs. With Sixth Street and KKR’s HealthCare Royalty backing, BridgeBio gains strategic partners capable of supporting its ambitious growth trajectory.
What we're watching
- Launch Execution
- The pace at which BridgeBio can successfully launch three blockbuster drugs within the next year will determine the ROI on this financing.
- Capital Allocation
- How BridgeBio allocates the $1 billion across its highest-return opportunities, balancing current launches and future R&D.
- Market Response
- Whether the >100% premium valuation sustains as BridgeBio transitions from development to commercialization at scale.
Related topics